An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
01 2019
Historique:
received: 14 05 2018
accepted: 30 06 2018
revised: 27 06 2018
pubmed: 26 8 2018
medline: 18 12 2019
entrez: 26 8 2018
Statut: ppublish

Résumé

The nuclear proliferation biomarker Ki67 has potential prognostic, predictive, and monitoring roles in breast cancer. Unacceptable between-laboratory variability has limited its clinical value. The International Ki67 in Breast Cancer Working Group investigated whether Ki67 immunohistochemistry can be analytically validated and standardized across laboratories using automated machine-based scoring. Sets of pre-stained core-cut biopsy sections of 30 breast tumors were circulated to 14 laboratories for scanning and automated assessment of the average and maximum percentage of tumor cells positive for Ki67. Seven unique scanners and 10 software platforms were involved in this study. Pre-specified analyses included evaluation of reproducibility between all laboratories (primary) as well as among those using scanners from a single vendor (secondary). The primary reproducibility metric was intraclass correlation coefficient between laboratories, with success considered to be intraclass correlation coefficient >0.80. Intraclass correlation coefficient for automated average scores across 16 operators was 0.83 (95% credible interval: 0.73-0.91) and intraclass correlation coefficient for maximum scores across 10 operators was 0.63 (95% credible interval: 0.44-0.80). For the laboratories using scanners from a single vendor (8 score sets), intraclass correlation coefficient for average automated scores was 0.89 (95% credible interval: 0.81-0.96), which was similar to the intraclass correlation coefficient of 0.87 (95% credible interval: 0.81-0.93) achieved using these same slides in a prior visual-reading reproducibility study. Automated machine assessment of average Ki67 has the potential to achieve between-laboratory reproducibility similar to that for a rigorously standardized pathologist-based visual assessment of Ki67. The observed intraclass correlation coefficient was worse for maximum compared to average scoring methods, suggesting that maximum score methods may be suboptimal for consistent measurement of proliferation. Automated average scoring methods show promise for assessment of Ki67 scoring, but requires further standardization and subsequent clinical validation.

Identifiants

pubmed: 30143750
doi: 10.1038/s41379-018-0109-4
pii: S0893-3952(22)01104-8
doi:

Substances chimiques

Biomarkers, Tumor 0
Ki-67 Antigen 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-69

Auteurs

David L Rimm (DL)

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. david.rimm@yale.edu.

Samuel C Y Leung (SCY)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Lisa M McShane (LM)

Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.

Yalai Bai (Y)

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

Anita L Bane (AL)

Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada.

John M S Bartlett (JMS)

Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, UK.

Jane Bayani (J)

Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada.

Martin C Chang (MC)

Sinai Health System, University of Toronto, Toronto, ON, Canada.

Michelle Dean (M)

Translational Laboratories, Alberta Health Services, Tom Baker Cancer Centre, Calgary, AB, Canada.

Carsten Denkert (C)

Institut für Pathologie and German Cancer Consortium (DKTK), Charité Campus Mitte, Berlin, Germany.

Emeka K Enwere (EK)

Translational Laboratories, Alberta Health Services, Tom Baker Cancer Centre, Calgary, AB, Canada.

Chad Galderisi (C)

MolecularMD, Portland, OR, USA.

Abhi Gholap (A)

Optra Technologies, NeoPro SEZ, Blue Ridge, Hinjewadi, India.

Judith C Hugh (JC)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Anagha Jadhav (A)

Optra Technologies, NeoPro SEZ, Blue Ridge, Hinjewadi, India.

Elizabeth N Kornaga (EN)

Translational Laboratories, Alberta Health Services, Tom Baker Cancer Centre, Calgary, AB, Canada.

Arvydas Laurinavicius (A)

National Center of Pathology, Vilnius University Hospital Santara Clinics, Vilnius University, Vilnius, Lithuania.

Richard Levenson (R)

Department of Medical Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA.

Joema Lima (J)

Transformative Pathology, Ontario Institute for Cancer Research, Toronto, ON, Canada.

Keith Miller (K)

Cancer Diagnostic Quality Assurance Services CIC, Poundbury Cancer Institute, Poundbury, DT, UK.

Liron Pantanowitz (L)

Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

Tammy Piper (T)

Biomarkers & Companion Diagnostics Group, Edinburgh Cancer Research Centre, Edinburgh, UK.

Jason Ruan (J)

Department of Medical Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, CA, USA.

Malini Srinivasan (M)

Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.

Shakeel Virk (S)

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

Ying Wu (Y)

Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada.

Hua Yang (H)

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Daniel F Hayes (DF)

Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

Torsten O Nielsen (TO)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Mitch Dowsett (M)

Institute of Cancer Research, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH